CA-102N is under clinical development by Holy Stone Healthcare and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CA-102N’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CA-102N overview
CA-102N is under development for the treatment of solid tumors including colorectal cancer. It is a carrier-mediated drug delivery product where hyaluronic acid is conjugated to Nimuselide-NH2.It is administered as an intravenous infusion solution. It is developed as Hyaluronic Acid Conjugated Drug (HACD). It acts by targeting CD44.
Holy Stone Healthcare overview
Holy Stone Healthcare is a Taiwan-based company principally engaged in the manufacture and wholesale of medical equipment. The Company’s main products include latent tuberculosis infection test reagents, Ostenil branded joint cavity injection and o
For a complete picture of CA-102N’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
